Piper Sandler Maintains Overweight on TransMedics Gr, Maintains $180 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien has reiterated an Overweight rating on TransMedics Group (NASDAQ:TMDX) with a maintained price target of $180.
October 07, 2024 | 5:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has reiterated an Overweight rating for TransMedics Group with a price target of $180, indicating confidence in the company's potential for growth.
The reaffirmation of an Overweight rating and a $180 price target by Piper Sandler suggests a positive outlook for TransMedics Group. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100